# Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors

> **NCT07299747** · PHASE1,PHASE2 · RECRUITING · sponsor: **VelaVigo Bio Inc** · enrollment: 255 (estimated)

## Conditions studied

- Participants With Advanced Solid Tumor Malignancies

## Interventions

- **DRUG:** VBC103

## Key facts

- **NCT ID:** NCT07299747
- **Lead sponsor:** VelaVigo Bio Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-04
- **Primary completion:** 2027-12-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 255 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07299747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07299747, "Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07299747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*